Valuation: Capnia Inc

Market Cap 2.76B 2.42B 2.23B 2.06B 3.87B 266B 3.96B 26.62B 10.47B 130B 10.38B 10.15B 449B P/E 2024
-10.3x
P/E 2025 119x
Enterprise Value 2.31B 2.02B 1.87B 1.72B 3.24B 222B 3.31B 22.25B 8.75B 109B 8.67B 8.48B 375B EV / Sales 2024
-
EV / Sales 2025 10,678,497x
Free-Float
98.88%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 61 15/05/2026
Treasurer 46 15/05/2026
Director TitleAgeSince
Director/Board Member 61 15/05/2026
Director/Board Member 46 15/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.77%-2.62%+40.54%+184.05% 25.95B
Weighted average by Cap. -2.80%-2.36%+39.55%+143.13%

Financials

2024 2025
Net sales - 190.4 166.61 153.91 141.63 266.89 18.33K 273.1 1.83K 721.69 8.96K 715.01 699.28 30.94K
Net income -176M -154M -142M -131M -246M -16.93B -252M -1.69B -667M -8.28B -660M -646M -28.58B 20.89M 18.28M 16.89M 15.54M 29.28M 2.01B 29.96M 201M 79.18M 983M 78.45M 76.72M 3.39B
Net Debt -266M -233M -215M -198M -373M -25.59B -381M -2.56B -1.01B -12.51B -998M -976M -43.2B -454M -397M -367M -337M -636M -43.66B -651M -4.37B -1.72B -21.35B -1.7B -1.67B -73.7B
Logo Capnia Inc
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder. The Company sells its product primarily to a specialty pharmacy.
Employees
-